Dopamine agonist therapy in Parkinson's disease: Spanish expert consensus on its use in different clinical situations
Diego Santos García 1 , Javier Pagonabarraga Mora 2 , Francisco Escamilla Sevilla 3 , Pedro J García Ruiz 4 , Jon Infante Ceberio 5 , Jaime Kulisevsky Bojarski 2 , Gurutz Linazasoro Cristóbal 6 , María Rosario Luquín Piudo 7 , Juan Carlos Martínez Castrillo 8 , Silvia Jesús Maestre 9 , Lydia Vela Desojo 10 , Francisco J Campos Lucas 11 , Fernando Caballero Martínez 11 , Pablo Mir 12 ; Panel of Experts Phase 1
Background: Different types of therapies were proven effective for the medical management of motor and non-motor symptoms in Parkinson's disease (PD). We aimed to gain consensus on the Dopamine agonist (DA) therapy use in different clinical scenarios of Parkinson's disease (PD) patients.
Methods: This consensus study was based on the nominal group technique. Initially, a Consensus Group comprising 12 expert neurologists in the PD field identified the topics to be addressed and elaborated different evidence-based preliminary statements. Next, a panel of 48 Spanish neurologists expressed their opinion on an internet-based systematic voting program. Finally, initial ideas were reviewed and rewritten according to panel contribution and were ranked by the Consensus group using a Likert-type scale. The analysis of data was carried out by using a combination of both qualitative and quantitative methods. The consensus was achieved if the statement reached ≥3,5 points on the voting process.
Results: The Consensus Group produced 76 real-world recommendations. The topics addressed included 12 statements related to DA therapy in early PD, 20 statements concerning DA treatment strategy in patients with motor complications, 11 statements associated with DA drugs and their side effects, and 33 statements regarding DA therapy in specific clinical scenarios. The Consensus Group did not reach a consensus on 15 statements.
Conclusion: The findings from this consensus method represent an exploratory step to help clinicians and patients in the appropriate use of DA in different stages and clinical situations of PD.
CITATION Neurologia (Engl Ed). 2023 Jul 5;S2173-5808(23)00037-8. doi: 10.1016/j.nrleng.2023.04.008